Cooper Co (COO) AI Stock Analysis

• Market Cap: $15.88B
• Dividend Yield: N/A
• Average Volume (3M): 3.09M
• Price to Earnings (P/E): 44.0
• Beta (1Y): 0.77
• Revenue Growth: 5.06%
• EPS Growth: -4.47%
• Country: US
• Employees: 16,000
• Sector: N/A
• Sector Strength: N/A
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.15
• Shares Outstanding: 195,978,030
• 10 Day Avg. Volume: 4,374,760
• 30 Day Avg. Volume: 3,092,720
• PEG Ratio: -7.35
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 3.42
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.04
• Enterprise Value/Revenue: 4.08
• Enterprise Value/Gross Profit: 6.10
• Enterprise Value/Ebitda: 15.15
• 1Y Price Target: $89.67
• Price Target Upside: 10.65% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): 4.53
• Revenue Forecast (FY): $4.32B

• Rating: 76 Outperform
• Price Target: $88.00 ▲(8.59% Upside)

Cooper Co's overall stock score is driven by strong technical indicators and solid financial performance, despite valuation concerns. The company's strategic initiatives and growth prospects, particularly in CooperVision, are positive, but challenges in certain markets and high valuation metrics temper the score.

Cooper Co Business Overview & Revenue Model

Company Description

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

How the Company Makes Money

Cooper Co generates revenue through multiple key streams, including direct sales of its consumer goods through retail channels, online marketplaces, and wholesale distribution. The company also engages in strategic partnerships with major retailers and e-commerce platforms, which provide significant exposure and increased sales volume. Additionally, Cooper Co invests in brand development and marketing initiatives to enhance product visibility and consumer loyalty, thereby driving repeat purchases. The company also explores licensing agreements for its products, allowing for additional revenue through royalties while expanding its market reach.

Cooper Co Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Cooper Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 81.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COO, the sentiment is Positive. The current price of 81.04 is above the 20-day moving average (MA) of 77.64, above the 50-day MA of 73.73, and above the 200-day MA of 74.54, indicating a bullish trend. The MACD of 2.44 indicates Negative momentum. The RSI at 63.67 is Neutral, neither overbought nor oversold. The STOCH value of 42.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for COO.

Cooper Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
COO	76 Outperform	$15.88B	44.02	4.59%	―	5.06%	-4.47%
HOLX	69 Neutral	$16.73B	30.18	11.12%	―	1.74%	-25.29%
WST	68 Neutral	$19.17B	39.46	16.94%	0.32%	4.90%	-0.26%
ATR	60 Neutral	$8.06B	19.68	15.80%	1.49%	2.50%	25.05%
MASI	54 Neutral	$7.23B	-12.80	-17.93%	―	-16.03%	-813.48%
BAX	45 Neutral	$9.79B	-37.00	-4.70%	2.73%	-21.20%	-325.40%

Cooper Co Corporate Events

Cooper Co Announces Leadership Change Amid Financial Growth

On December 4, 2025, CooperCompanies announced that Robert S. Weiss resigned as Chairman of the Board, effective January 2, 2026, with Colleen E. Jay appointed as his successor. The company also reported its financial results for the fiscal fourth quarter and full year ending October 31, 2025, showing a 5% increase in revenue to $4.1 billion and a 12% rise in non-GAAP EPS to $4.13, despite a 4% decline in GAAP EPS. The company aims to drive long-term shareholder value through growth, profitability, and strategic investments.